MRK logo Merck & Co. +
Merck & Co.
+

Merck & Co. (MRK) Business News

Track Merck & Co. in real time with a live news feed covering Merck & Co. stock news, official press releases, company announcements, and an archive of historical Merck & Co. news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
6:45 AM | Tuesday | May 12, 2026 Business Wire

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

News Thumbnail
2:05 PM | Thursday | May 7, 2026 Business Wire

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

News Thumbnail
9:00 AM | Wednesday | May 6, 2026 Business Wire

Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees

News Thumbnail
8:45 AM | Tuesday | May 5, 2026 Business Wire

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

News Thumbnail
8:05 AM | Thursday | Apr 30, 2026 Business Wire

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations

News Thumbnail
6:30 AM | Thursday | Apr 30, 2026 Business Wire

Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones

News Thumbnail
6:45 AM | Tuesday | Apr 28, 2026 Business Wire

Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

News Thumbnail
6:45 AM | Friday | Apr 24, 2026 Business Wire

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

News Thumbnail
8:00 AM | Wednesday | Apr 22, 2026 PRNewsWire

Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation

News Thumbnail
6:45 AM | Tuesday | Apr 21, 2026 Business Wire

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

News Thumbnail

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

Business Wire

6:45 AM | Tuesday | May 12, 2026

news photo
Loading...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of cancer from the company's comprehensive oncology portfolio and pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-June 2). The data reinforce the long-term impact of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, and Merck's rapidly advancing pipelin.

Read full article redirect
6:45 AM | Tuesday | May 12, 2026

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of cancer from the company's comprehensive oncology portfolio and pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-June 2). The data reinforce the long-term impact of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, and Merck's rapidly advancing pipelin.

Read full article arrow
News Thumbnail
2:05 PM | Thursday | May 7, 2026

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoate, the company's investigational oral PCSK9 inhibitor, using a tailored suite of enzymes in the latest issue of the peer reviewed journal Science. “Macrocyclic peptides have the potential to unlock new opportunities to develop oral treatment options for challenging therapeutic targets and broaden p.

Read full article arrow
News Thumbnail
9:00 AM | Wednesday | May 6, 2026

Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees

Business Wire

SAN FRANCISCO & RAHWAY, N.J.--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 AI CRM, and Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc. (NYSE: MRK), today announced that Merck Animal Health has selected Agentforce Life Sciences for Customer Engagement to create a unified, 360-degree view and support experience for veterinarians, pet owners, and production animal farmers across all channels.
Leveraging Agentfo.

Read full article arrow
News Thumbnail
8:45 AM | Tuesday | May 5, 2026

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). “The Terns acquisition reflects Merck's continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to patients,” said Robert M.
Davis, chairman and chief executive officer, Merck. “We believe TERN‑701 has the potential to be.

Read full article arrow
News Thumbnail
8:05 AM | Thursday | Apr 30, 2026

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations

Business Wire

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinr.

Read full article arrow
News Thumbnail
6:30 AM | Thursday | Apr 30, 2026

Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.
J., USA Announces First-Quarter 2026 Financial Results.

Read full article arrow
News Thumbnail
6:45 AM | Tuesday | Apr 28, 2026

Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional baseball players to launch the Playing with Heart educational program to help educate adults about the importance of knowing their low-density lipoprotein cholesterol (LDL-C), called “bad” cholesterol, number and the potential increased risk of heart attack or stroke. Playing with Heart connects Merc.

Read full article arrow
News Thumbnail
6:45 AM | Friday | Apr 24, 2026

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Merck's pending acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN) expired at 11:59 p.m.
, Eastern Time, on April 23, 2026. As previously announced on April 7, 2026, Merck commenced, through a subsidiary, a cash tender offer to purchase.

Read full article arrow
News Thumbnail
8:00 AM | Wednesday | Apr 22, 2026

Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation

PRNewsWire

New collaboration taps Gemini Enterprise to realize business-driving value, innovation and patient impact across the next era of biopharmaceutical growth LAS VEGAS, April 22, 2026 /PRNewswire/ -- Cloud Next '26 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enhance Merck's digital backbone as an AI-enabled enterprise. This multi-year investment, valued at up to $1 billion, will deploy an agentic platform  across Merck's research & development (R&D), manufacturing, commercial, and corporate functions—and includes Google Cloud engineers working alongside Merck teams to deploy Google Cloud's most sophisticated AI, including Gemini Enterprise.

Read full article arrow
News Thumbnail
6:45 AM | Tuesday | Apr 21, 2026

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

Business Wire

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced RCC.

Read full article arrow
News Thumbnail